A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer.
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2016
At a glance
- Drugs Interferon alpha (Primary) ; Oblimersen (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 19 Dec 2012 Actual initiation date changed from Feb 2003 to Aug 2003 as reported by ClinicalTrials.gov.
- 23 Jun 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 03 Sep 2005 New trial record.